Sumitomo Mitsui Trust Group Inc. Cuts Holdings in CVS Health Corporation $CVS

Sumitomo Mitsui Trust Group Inc. trimmed its holdings in shares of CVS Health Corporation (NYSE:CVS) by 3.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,868,224 shares of the pharmacy operator’s stock after selling 91,148 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.23% of CVS Health worth $227,622,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Brown Lisle Cummings Inc. grew its holdings in CVS Health by 5.7% in the fourth quarter. Brown Lisle Cummings Inc. now owns 13,604 shares of the pharmacy operator’s stock worth $1,080,000 after purchasing an additional 731 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in shares of CVS Health by 7.9% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 3,338,744 shares of the pharmacy operator’s stock worth $264,963,000 after buying an additional 243,501 shares during the period. Ritholtz Wealth Management lifted its stake in shares of CVS Health by 11.4% during the fourth quarter. Ritholtz Wealth Management now owns 17,759 shares of the pharmacy operator’s stock worth $1,409,000 after buying an additional 1,819 shares during the period. Diversify Advisory Services LLC lifted its stake in shares of CVS Health by 8.2% during the fourth quarter. Diversify Advisory Services LLC now owns 19,795 shares of the pharmacy operator’s stock worth $1,556,000 after buying an additional 1,494 shares during the period. Finally, Carnegie Investment Counsel acquired a new position in CVS Health during the fourth quarter valued at $3,864,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Sanford C. Bernstein upgraded shares of CVS Health from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $91.00 to $94.00 in a research report on Thursday, March 12th. Bank of America decreased their target price on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research report on Tuesday, January 27th. The Goldman Sachs Group upped their price objective on shares of CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a research report on Thursday, February 12th. Argus decreased their price objective on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, January 28th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $98.00 price objective on shares of CVS Health in a research report on Thursday, March 5th. Twenty research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $94.95.

CVS Health Trading Down 0.1%

Shares of CVS Health stock opened at $79.29 on Monday. The company has a market cap of $101.61 billion, a P/E ratio of 57.45, a price-to-earnings-growth ratio of 0.83 and a beta of 0.51. The firm has a 50-day simple moving average of $75.92 and a two-hundred day simple moving average of $77.81. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. CVS Health Corporation has a fifty-two week low of $58.35 and a fifty-two week high of $85.15.

CVS Health (NYSE:CVS) last released its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The business had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd will be paid a dividend of $0.665 per share. The ex-dividend date of this dividend is Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.4%. CVS Health’s payout ratio is currently 192.75%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.